Cargando…

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfuncti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuan, Flynn, Elizabeth R., do Carmo, Jussara M., Wang, Zhen, da Silva, Alexandre A., Mouton, Alan J., Omoto, Ana C. M., Hall, Michael E., Hall, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135142/
https://www.ncbi.nlm.nih.gov/pubmed/35647080
http://dx.doi.org/10.3389/fcvm.2022.859253
_version_ 1784713899864489984
author Li, Xuan
Flynn, Elizabeth R.
do Carmo, Jussara M.
Wang, Zhen
da Silva, Alexandre A.
Mouton, Alan J.
Omoto, Ana C. M.
Hall, Michael E.
Hall, John E.
author_facet Li, Xuan
Flynn, Elizabeth R.
do Carmo, Jussara M.
Wang, Zhen
da Silva, Alexandre A.
Mouton, Alan J.
Omoto, Ana C. M.
Hall, Michael E.
Hall, John E.
author_sort Li, Xuan
collection PubMed
description Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfunction and oxidative stress play important roles in progression of HF. This study tested the hypothesis that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves mitochondrial function and reduces reactive oxygen species (ROS) while enhancing cardiac performance through direct effects on the heart in a non-diabetic mouse model of HF induced by transverse aortic constriction (TAC). EMPA or vehicle was administered orally for 4 weeks starting 2 weeks post-TAC. EMPA treatment did not alter blood glucose or body weight but significantly attenuated TAC-induced cardiac dysfunction and ventricular remodeling. Impaired mitochondrial oxidative phosphorylation (OXPHOS) in failing hearts was significantly improved by EMPA. EMPA treatment also enhanced mitochondrial biogenesis and restored normal mitochondria morphology. Although TAC increased mitochondrial ROS and decreased endogenous antioxidants, EMPA markedly inhibited cardiac ROS production and upregulated expression of endogenous antioxidants. In addition, EMPA enhanced autophagy and decreased cardiac apoptosis in TAC-induced HF. Importantly, mitochondrial respiration significantly increased in ex vivo cardiac fibers after direct treatment with EMPA. Our results indicate that EMPA has direct effects on the heart, independently of reductions in blood glucose, to enhance mitochondrial function by upregulating mitochondrial biogenesis, enhancing OXPHOS, reducing ROS production, attenuating apoptosis, and increasing autophagy to improve overall cardiac function in a non-diabetic model of pressure overload-induced HF.
format Online
Article
Text
id pubmed-9135142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91351422022-05-27 Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure Li, Xuan Flynn, Elizabeth R. do Carmo, Jussara M. Wang, Zhen da Silva, Alexandre A. Mouton, Alan J. Omoto, Ana C. M. Hall, Michael E. Hall, John E. Front Cardiovasc Med Cardiovascular Medicine Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for cardioprotection by SGLT2 inhibitors are still unclear. Mitochondrial dysfunction and oxidative stress play important roles in progression of HF. This study tested the hypothesis that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves mitochondrial function and reduces reactive oxygen species (ROS) while enhancing cardiac performance through direct effects on the heart in a non-diabetic mouse model of HF induced by transverse aortic constriction (TAC). EMPA or vehicle was administered orally for 4 weeks starting 2 weeks post-TAC. EMPA treatment did not alter blood glucose or body weight but significantly attenuated TAC-induced cardiac dysfunction and ventricular remodeling. Impaired mitochondrial oxidative phosphorylation (OXPHOS) in failing hearts was significantly improved by EMPA. EMPA treatment also enhanced mitochondrial biogenesis and restored normal mitochondria morphology. Although TAC increased mitochondrial ROS and decreased endogenous antioxidants, EMPA markedly inhibited cardiac ROS production and upregulated expression of endogenous antioxidants. In addition, EMPA enhanced autophagy and decreased cardiac apoptosis in TAC-induced HF. Importantly, mitochondrial respiration significantly increased in ex vivo cardiac fibers after direct treatment with EMPA. Our results indicate that EMPA has direct effects on the heart, independently of reductions in blood glucose, to enhance mitochondrial function by upregulating mitochondrial biogenesis, enhancing OXPHOS, reducing ROS production, attenuating apoptosis, and increasing autophagy to improve overall cardiac function in a non-diabetic model of pressure overload-induced HF. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9135142/ /pubmed/35647080 http://dx.doi.org/10.3389/fcvm.2022.859253 Text en Copyright © 2022 Li, Flynn, do Carmo, Wang, da Silva, Mouton, Omoto, Hall and Hall. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Li, Xuan
Flynn, Elizabeth R.
do Carmo, Jussara M.
Wang, Zhen
da Silva, Alexandre A.
Mouton, Alan J.
Omoto, Ana C. M.
Hall, Michael E.
Hall, John E.
Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title_full Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title_fullStr Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title_full_unstemmed Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title_short Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
title_sort direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135142/
https://www.ncbi.nlm.nih.gov/pubmed/35647080
http://dx.doi.org/10.3389/fcvm.2022.859253
work_keys_str_mv AT lixuan directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT flynnelizabethr directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT docarmojussaram directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT wangzhen directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT dasilvaalexandrea directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT moutonalanj directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT omotoanacm directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT hallmichaele directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure
AT halljohne directcardiacactionsofsodiumglucosecotransporter2inhibitionimprovemitochondrialfunctionandattenuateoxidativestressinpressureoverloadinducedheartfailure